- Evolocumab added to statins is linked to decreased event rates for myocardial infarction (MI), stroke, and coronary revascularisation.
- These results from a prespecified secondary analysis of the FOURIER trial support “the benefit of continuing aggressive lipid-lowering therapy” for secondary prevention, say the authors.
Why this matters
- Results of the primary analysis showed benefit of evolocumab in primary prevention.
- The intervention group experienced reduced subsequent primary outcome events vs placebo: incidence rate ratio, 0.74 (95% CI, 0.65-0.85).
- For every 1000 patients treated for 3 years, evolocumab was tied to 30 prevented second primary outcome events.
- Most of the prevented second events (rate ratios; 95% CIs) were:
- MI: 0.74 (0.65-0.84),
- Stroke: 0.77 (0.64-0.93), and
- Coronary revascularisation: 0.78 (0.71-0.87).
- Cardiovascular death rate was similar between the 2 trial groups.
- Randomised, placebo-controlled, double-blind trial of 27,564 patients with stable atherosclerotic disease on statins.
- Primary endpoint: time to first cardiovascular death, MI, stroke, hospitalisation for unstable angina, coronary revascularisation.
- Total cardiovascular events also analysed.
- Funding: Amgen.
- Relatively short follow-up of median 2.2 years.